Product
Pevonedistat
Aliases
MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, TAK-924
21 clinical trials
66 indications
Indication
Acute Myeloid LeukemiaIndication
CancerIndication
LeukemiaIndication
myeloidIndication
AcuteIndication
Myelodysplastic SyndromesIndication
MyelomonocyticIndication
ChronicIndication
Chronic Kidney DiseaseIndication
Liver DiseaseIndication
Recurrent Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Stage IIIB Lung CancerIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
Lung CancerIndication
Therapy-Related Acute Myeloid LeukemiaIndication
Atypical chronic myeloid leukemiaIndication
BCR-ABL1 NegativeIndication
Chronic Eosinophilic LeukemiaIndication
NOSIndication
Chronic Myelomonocytic LeukemiaIndication
Chronic Neutrophilic LeukemiaIndication
Essential ThrombocythemiaIndication
UnclassifiableIndication
Myeloid NeoplasmIndication
Myeloproliferative NeoplasmIndication
Primary MyelofibrosisIndication
Polycythemia VeraIndication
Post-Polycythemic Myelofibrosis PhaseIndication
Prefibrotic/Early Primary MyelofibrosisIndication
B-Cell Prolymphocytic LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
Recurrent Follicular LymphomaIndication
Lymphoplasmacytic LymphomaIndication
Mantle Cell LymphomaIndication
Marginal Zone LymphomaIndication
Non-Hodgkin LymphomaIndication
Small Lymphocytic LymphomaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Diffuse Large B-Cell LymphomaIndication
Follicular LymphomaIndication
Waldenström macroglobulinemiaIndication
Refractory Non-Hodgkin LymphomaIndication
Richter syndromeIndication
CholangiocarcinomaIndication
Hepatocellular CarcinomaIndication
Intrahepatic CholangiocarcinomaIndication
Stage IIIA Hepatocellular CarcinomaIndication
intrahepatic cholangiocarcinomaIndication
Multiple MyelomaIndication
LymphomaIndication
Recurrent Malignant Solid NeoplasmIndication
Malignant Solid NeoplasmIndication
NSCLCClinical trial
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2022-09-06
Clinical trial
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2019-01-07
Clinical trial
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic ImpairmentStatus: Completed, Estimated PCD: 2021-03-19
Clinical trial
A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
Expanded Access Program: Pevonedistat (in Combination With Azacitidine) for the First-line Treatment of Higher Risk Myelodysplastic SyndromesStatus:
Clinical trial
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous LeukemiaStatus: Completed, Estimated PCD: 2019-09-04
Clinical trial
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2022-09-07
Clinical trial
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)Status: Active (not recruiting), Estimated PCD: 2024-10-13
Clinical trial
A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)Status: Terminated, Estimated PCD: 2021-12-12
Clinical trial
A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AMLStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-06-22
Clinical trial
A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsStatus: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic CholangiocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b TrialStatus: Completed, Estimated PCD: 2022-09-12
Clinical trial
Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2021-11-04
Clinical trial
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-09-30
Clinical trial
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Randomized Phase II Trial of MLN4924 (Pevonedistat) With Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid LeukemiaStatus: Withdrawn, Estimated PCD: 2021-08-19
Clinical trial
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous LeukemiaStatus: Active (not recruiting), Estimated PCD: 2021-05-28